BRIEF-BeOne Medicines Announces Positive Phase 3 Results For BRUKINSA In Frontline Mantle Cell Lymphoma

June 30 (Reuters) - BeOne Medicines AG 688235.SS:

  • BEONE MEDICINES ANNOUNCES POSITIVE PHASE 3 RESULTS FOR BRUKINSA IN FRONTLINE MANTLE CELL LYMPHOMA

  • BEONE MEDICINES: BRUKINSA-BASED, CHEMOTHERAPY-FREE REGIMEN LED TO 43% REDUCTION IN RISK OF PROGRESSION OR DEATH

  • BEONE MEDICINES: GLOBAL REGULATORY SUBMISSIONS FROM MANGROVE FIRST PHASE 3 TRIAL PLANNED FOR 2H 2026

  • BEONE MEDICINES: TRIAL MET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.